New England Research & Management Inc. Decreases Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

New England Research & Management Inc. cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,640 shares of the biotechnology company's stock after selling 2,080 shares during the quarter. United Therapeutics makes up about 1.0% of New England Research & Management Inc.'s portfolio, making the stock its 28th largest position. New England Research & Management Inc.'s holdings in United Therapeutics were worth $1,990,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of the stock. Creative Planning lifted its holdings in shares of United Therapeutics by 20.1% in the 2nd quarter. Creative Planning now owns 3,613 shares of the biotechnology company's stock worth $1,151,000 after purchasing an additional 605 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its stake in shares of United Therapeutics by 10.2% in the second quarter. B. Riley Wealth Advisors Inc. now owns 1,067 shares of the biotechnology company's stock valued at $340,000 after buying an additional 99 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of United Therapeutics by 8.7% during the second quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company's stock valued at $1,964,000 after buying an additional 493 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in shares of United Therapeutics during the second quarter worth about $3,471,000. Finally, SG Americas Securities LLC raised its holdings in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company's stock worth $535,000 after acquiring an additional 594 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christopher Causey sold 510 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares of the company's stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 149,048 shares of company stock valued at $56,142,199. 11.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on UTHR shares. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Finally, HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $378.36.

United Therapeutics Trading Down 5.4 %

Shares of UTHR stock traded down $20.26 during trading on Thursday, reaching $352.49. 269,949 shares of the company's stock traded hands, compared to its average volume of 278,004. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82. The company has a market capitalization of $15.74 billion, a P/E ratio of 15.50, a PEG ratio of 0.95 and a beta of 0.57. The firm's 50-day moving average is $365.77 and its 200 day moving average is $356.81.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. During the same quarter in the prior year, the firm posted $5.38 EPS. The firm's quarterly revenue was up 22.9% on a year-over-year basis. As a group, sell-side analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.